GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58
Manufacturer # 00006412102
Brand Gardasil® 9
Manufacturer Merck
Country of Origin United States
Application Human Papillomavirus Vaccine (HPV)
Container Type Prefilled Syringe
Dosage Form Injection
Generic Drug Code 37568
Generic Drug Name Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free
Is_Active_Vendor Y
Is_DSCSA Y
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag Y
NDC Number 00006412102
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires Refrigeration
Strength 20 mcg - 60 mcg / 0.5 mL
Supplier_ID 3885337
Type Intramuscular
UNSPSC Code 51201649
User Indicated for People 9 to 45 Years of Age
Volume 0.5 mL
